Biomarin Pharmaceutical (BMRN) Assets Average (2010 - 2026)

Biomarin Pharmaceutical has disclosed Assets Average across 17 years of filings, most recently posting $8.1 billion for Q1 2026.

• Quarterly Assets Average rose 14.5% year-over-year to $8.1 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.1 billion (up 14.5% YoY) and the FY2025 annual result came in at $7.3 billion, up 5.44% from the prior year.
• Assets Average grew to $8.1 billion in Q1 2026, from $7.6 billion in the prior quarter.
• Over five years, Assets Average peaked at $8.1 billion in Q1 2026 and troughed at $6.0 billion in Q1 2022.
• A 5-year average of $6.8 billion and a median of $6.9 billion in 2024 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2024 — Assets Average climbed 1.77% — and 2026, when it advanced 14.5%.
• Tracing BMRN's Assets Average over 5 years: stood at $6.3 billion in 2022, then increased by 7.6% to $6.8 billion in 2023, then advanced by 1.77% to $6.9 billion in 2024, then climbed by 9.89% to $7.6 billion in 2025, then gained by 6.42% to $8.1 billion in 2026.
• Business Quant data shows BMRN's Assets Average at $8.1 billion in Q1 2026, $7.6 billion in Q4 2025, and $7.5 billion in Q3 2025.